A
Agilent Technologies, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 152.88K | $24.44M | n/a | n/a |
| Q2 2026 | 164 | +3 | 194.45M | $25.84B | +9 | −7 |
| Q1 2026 | 165 | -3 | 181.10M | $20.68B | +3 | −7 |
| Q4 2025 | 167 | +1 | 200.20M | $27.23B | +3 | −1 |
| Q3 2025 | 22 | +2 | 109.95M | $14.10B | +3 | −2 |
| Q2 2025 | 18 | -1 | 102.37M | $12.08B | n/a | −1 |
| Q1 2025 | 16 | -1 | 41.13M | $4.81B | n/a | −1 |
| Q4 2024 | 17 | +1 | 41.24M | $5.54B | +2 | −1 |
| Q3 2024 | 15 | -1 | 26.67M | $3.96B | +1 | −2 |
| Q2 2024 | 16 | n/a | 29.82M | $3.86B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 9.53M | n/a | $1.24B | 0.2% | n/c | 1 | SEC ↗ ×8 |
| 2 | Geode Capital Management ✦ (passive) | 6.92M | n/a | $894.40M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 3.11M | n/a | $402.64M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 2.91M | n/a | $376.65M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | PRIMECAP Management ✦ | 1.96M | n/a | $253.63M | 0.2% | n/c | 1 | SEC ↗ |
| 6 | Harris Associates (Oakmark) ✦ | 1.89M | n/a | $244.85M | 0.4% | n/c | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 992.33K | n/a | $128.64M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 957.13K | n/a | $124.07M | 0.2% | n/c | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 875.15K | n/a | $113.45M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 215.76K | n/a | $27.97M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 184.78K | n/a | $23.95M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Adage Capital Partners ✦ | 131.09K | n/a | $16.99M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Soros Fund Management ✦ | 100.00K | n/a | $12.96M | 0.4% | n/c | 1 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 26.28K | n/a | $3.41M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 22.00K | n/a | $2.85M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 4.32K | n/a | $559,742 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,065 holders, 251.21M shares, $26.86B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 634 sh · $95,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology